Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data

[1]  M. Intorcia,et al.  Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States , 2017, Cancer medicine.

[2]  A. Avilés,et al.  Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients , 2017, Clinical lymphoma, myeloma & leukemia.

[3]  O. Landgren,et al.  Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes , 2017, Journal of internal medicine.

[4]  John D. Roberts,et al.  Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial , 2017, JAMA.

[5]  A. Liede,et al.  Utilization Patterns of Bone-Targeting Agents Among Patients with Multiple Myeloma: Analysis of Real-World Data , 2015 .

[6]  M. Morawska,et al.  Optimizing the treatment of patients with multiple myeloma and renal impairment. , 2015, Clinical lymphoma, myeloma & leukemia.

[7]  D. Dingli,et al.  Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma , 2014, Blood Cancer Journal.

[8]  G. Morgan,et al.  International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Prommer.  Toxicity of bisphosphonates. , 2009, Journal of palliative medicine.

[10]  M. Dimopoulos,et al.  Pathogenesis and management of myeloma bone disease , 2009, Expert review of hematology.

[11]  M. Drake,et al.  Adverse effects of bisphosphonates: implications for osteoporosis management. , 2009, Mayo Clinic proceedings.

[12]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[13]  I. Borrello.  Lenalidomide in renal insufficiency – balancing the risks and benefits , 2009, British journal of haematology.

[14]  W. Lewis,et al.  Multiple myeloma: diagnosis and treatment. , 2008, American family physician.

[15]  E. Kastritis,et al.  Pathogenesis and treatment of renal failure in multiple myeloma , 2008, Leukemia.

[16]  T. Economopoulos,et al.  Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance , 2007, Leukemia & lymphoma.

[17]  J. Goldman,et al.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. , 2003, Blood.

[18]  G. Mills,et al.  Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Knudsen,et al.  Renal failure in multiple myeloma: reversibility and impact on the prognosis , 2000, European journal of haematology.

[20]  R. Bell,et al.  Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[22]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[23]  Terry M Therneau,et al.  Review of 1027 patients with newly diagnosed multiple myeloma. , 2003, Mayo Clinic proceedings.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.